General information
BioNTech SE
An der Goldgrube 12
55131 Mainz, Rhineland-Palatinate
Germany
Contact person: Constanze Blume, Senior Vice President Global Regulatory Affairs
Company main phone: +49 (6131) 90840
Company main fax: +49 (6131) 90842121
Website: https://biontech.de
Year founded: | 2008
|
Source of foundation: | Spin-off from university |
Name of foundation source: | Johannes Gutenberg University Mainz |
No. of employees: |
Worldwide: 6133 |
Corporate description / mission:
BioNTech SE is a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company has several manufacturing sites capable of developing fully automated production processes for on-demand production of therapies and vaccines. The company's product BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with advanced melanoma.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2019
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Antibodies
- Antibody-drug-conjugate
- Cell therapy
- Immunotherapy
- Nucleic acid drugs
- Small molecules
- Vaccines
|
Primary therapeutic areas: |
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
|
Business model: |
- Manufacturer
- Service company
- Supplier / Distributor
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Distribution: |
- Indirect (independent dealer)
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 7 | |
Phase I: | 19 | |
Phase II: | 26 | |
Phase III: | 7 | |
On the market: | 3 | |
Description of products:
BNT111
BNT113
BNT116, etc.
Technology used:
mRNA-based Platforms
Protein-based Platforms
Cell Therapy-based Platforms
Small Molecule-based Platforms
Financing details
Market cap. / valuation: | USD 28'725.65M | |
Collaborations & Clients
Partnering strategy / collaborations:
Autolus Therapeutics
Bill & Melinda Gates Foundation
Biotheus
Coalition for Epidemic Preparedness Innovations (CEPI)
Crescendo Biologics
Duality Biologics
Fosun Pharma, etc.